Microbial Immunotherapy Composition for Low-Toxic Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including surgery, radiotherapy, chemotherapy, targeted therapy, and passive immunotherapy, fail to systematically address cancer and often result in irreversible harm to normal cells, impair the immune system, and have limited efficacy against metastasis, with T-cell-based immunotherapies showing low response rates and significant toxic side effects.
Innovation Solution
A pharmaceutical composition comprising microbial agents like Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi, combined with polyinosinic acid, polycytidylic acid, and vitamin, stimulates the innate immune system to activate adaptive immunity, enhancing T-cell responses and reducing treatment costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cell-based immunotherapies (PD-1/PD-L1 inhibitors) are used to stimulate adaptive immune responses, then cancer treatment is provided, but response rate remains low (10-25% across major tumor indications) and toxicity occurs
Solution Approach 1:
The patent combines innate immune stimulation (through microbial agents like Staphylococcus aureus, Bordetella pertussis, Salmonella typhi, and Salmonella paratyphi) with adaptive immune activation (through polyinosinic acid, polycytidylic acid, and vitamins) to create a synergistic immunotherapy that achieves higher response rates while reducing toxicity by leveraging multiple immune pathways simultaneously
Solution Approach 2:
The immunotherapy composition is designed to be universally applicable across multiple cancer types and stages by activating both innate and adaptive immune systems, providing broad-spectrum anti-tumor activity without requiring tumor-specific markers or having narrow indications, thereby improving response rate reliability across diverse malignancies
2Reliability
If CAR-T therapies are used to treat cancer, then significant and durable remissions are achieved in certain B-cell leukemia, lymphoma, and multiple myeloma subpopulations, but life-threatening cytokine release syndrome and neurotoxicity occur
Solution Approach 1:
The patent uses microbial agents and immune adjuvants as intermediary substances that safely bridge the gap between tumor recognition and immune activation, avoiding direct T cell engagement that causes cytokine release syndrome and neurotoxicity while still achieving effective tumor remission through controlled immune stimulation
3Reliability
If chemotherapy is used to kill cancer cells systemically, then cancer treatment is provided, but normal cells are non-selectively damaged causing irreversible harm and immune system impairment
Solution Approach 1:
The patent employs microbial agents that can be localized to the tumor microenvironment through antigen-specific recognition and immune cell recruitment, enabling cancer cell killing with minimal off-target effects on normal tissues, thereby maintaining local quality of treatment action while reducing systemic toxicity and immune impairment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively activates the immune system to kill cancer cells with minimal side effects, significantly reducing treatment costs and improving patient outcomes for various cancers, including metastatic lesions, while being applicable to other conditions like atherosclerosis and HPV infection.
Implementation Method 1
combined with polyinosinic acid, polycytidylic acid, and vitamin, stimulates both innate and adaptive immune responses to activate the immune system against cancer cells
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A pharmaceutical composition, and a preparation method therefor and a use thereof. The pharmaceutical composition comprises a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or adjuvant. The first active ingredient is a microbial agent comprising any one or more of staphylococcus aureus, bordetella pertussis, diphtheria toxoid, tetanus toxoid, typhoid bacillus or salmonella paratyphi. The second active ingredient comprises polyinosinic acid, polycytidylic acid, and a vitamin. The pharmaceutical composition relates to an artificial active immunization therapy for tumors, and can "stimulate" the entire immune system, so that the therapy of using bacteria to stimulate a human immune system so as to kill cancer cells is quite stable and reliable, and the lives of cancer patients can be significantly saved and prolonged. Additionally, the pharmaceutical composition has extremely high safety, extremely small toxic and side effects, and low preparation costs.